2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
34
Pheochromocytoma
14
Neuroendocrine Tumors
9
Paraganglioma
8
Recurrence
6
Neoplasms
6
Ganglioneuroblastoma
3
Neoplasm Metastasis
2
Neuroectodermal Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease
1
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
copper dotatate CU-64
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lutetium-177
1
Lutetium
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
3-Iodobenzylguanidine
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled